Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of Donepezil in the posterior variant of Alzheimers disease (Posterior Cortical Atrophy) Study

Next Previous
Trial Profile

Efficacy of Donepezil in the posterior variant of Alzheimers disease (Posterior Cortical Atrophy) Study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Donepezil (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms DONIPAD

Most Recent Events

  • 20 Jul 2017 Primary endpoint (Performance on the Mini Mental State Examination (MMSE) at 12 weeks) has not been met, according to results presented at the Alzheimer's Association International Conference 2017.
  • 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017.
  • 05 Jan 2012 Status changed from active, no longer recruiting to completed as reported by UKCRN.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top